Im Neuenheimer Feld 519
69120 Heidelberg, de
+49 (6221) 6510-300
febit and TGen Collaborate to Study New DNA Capture Method
febit’s HybSelectTM Technology Evaluated to Enable Targeting and Increase Speed for Next-Generation-Sequencing
febit's HybSelectTM Technology enables selective DNA capture and elution, an extremely efficient method to preselect sequences for Next-Generation Sequencers. HybSelect is based on febit's proven Geniom Technology and uses arrays within microfludic biochips for the selection process of targeted DNA. Geniom biochips are programmable and can contain any desired set of capture probes. The new method combines the extraordinary performance of latest sequencers with the efficient selection capabilities of Geniom Technology.
"We are delighted to have TGen as our first U.S. pilot user of HybSelect with the latest sequencing instrumentation," said Cord F. Staehler, president of febit. "We will obtain important data from TGen that will help us as we prepare for the official introduction of HybSelect in early 2009."
The collaboration provides TGen scientists pre-market access to a highly developed DNA capturing method.
"There's been a great deal of conversation on the future direction of genomic research centers on next generation sequencing," said Matthew Huentelman, Ph.D., TGen associate investigator and lead collaborator on this project. "This collaboration on the use and further development of this method enhances the opportunities for TGen researchers to make a difference in research utilizing next generation sequencing."
TGen has been a user of the Geniom One device for the production and microarray analysis of Geniom Biochips since 2006.
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen's vision is of a world where an understanding of genomic variation can be rapidly translated in a manner tailored to individual patients.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.